There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Argenx Se (ARGX), BeiGene Ltd (BGNE) and Agios Pharma (AGIO) with bullish sentiments.
Argenx Se (ARGX)
Cowen & Co. analyst Boris Peaker maintained a Buy rating on Argenx Se on December 4. The company’s shares closed on Friday at $101.61, close to its 52-week high of $111.43.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 5.5% and a 41.2% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $140.83, a 38.6% upside from current levels. In a report issued on December 3, Piper Jaffray also reiterated a Buy rating on the stock with a $161 price target.
.
See today’s analyst top recommended stocks >>
BeiGene Ltd (BGNE)
Cowen & Co. analyst Marc Frahm maintained a Buy rating on BeiGene Ltd on December 4. The company’s shares closed on Friday at $137.59.
According to TipRanks.com, Frahm is a 1-star analyst with an average return of -9.5% and a 22.7% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Adaptimmune Therapeutics, and Gritstone Oncology Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BeiGene Ltd with a $194.60 average price target, which is a 41.4% upside from current levels. In a report issued on November 21, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $174 price target.
.
Agios Pharma (AGIO)
Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Agios Pharma on December 4. The company’s shares closed on Friday at $53.17, close to its 52-week low of $51.37.
According to TipRanks.com, Shibutani is a 1-star analyst with an average return of -2.4% and a 35.6% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Lexicon Pharmaceuticals, and Pieris Pharmaceuticals.
Currently, the analyst consensus on Agios Pharma is a Moderate Buy with an average price target of $83.67, implying a 57.4% upside from current levels. In a report issued on November 30, Canaccord Genuity also reiterated a Buy rating on the stock with a $90 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
